Brown Capital Management LLC Sells 11,147 Shares of Insulet Co. (NASDAQ:PODD)

Brown Capital Management LLC lessened its stake in Insulet Co. (NASDAQ:PODD) by 58.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,806 shares of the medical instruments supplier’s stock after selling 11,147 shares during the period. Brown Capital Management LLC’s holdings in Insulet were worth $1,817,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Sei Investments Co. lifted its position in Insulet by 16.2% in the first quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock worth $2,019,000 after purchasing an additional 1,639 shares during the period. Bessemer Group Inc. boosted its position in shares of Insulet by 168.4% during the 1st quarter. Bessemer Group Inc. now owns 1,715 shares of the medical instruments supplier’s stock valued at $294,000 after acquiring an additional 1,076 shares in the last quarter. National Bank of Canada FI increased its stake in Insulet by 486.1% in the first quarter. National Bank of Canada FI now owns 96,734 shares of the medical instruments supplier’s stock valued at $16,048,000 after acquiring an additional 80,230 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its position in Insulet by 124.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,131 shares of the medical instruments supplier’s stock worth $537,000 after purchasing an additional 1,736 shares in the last quarter. Finally, Natixis bought a new position in Insulet during the first quarter worth about $3,610,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PODD shares. UBS Group increased their target price on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a report on Friday, August 9th. Barclays increased their price objective on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Canaccord Genuity Group increased their target price on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Citigroup boosted their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Stock Up 1.8 %

Shares of PODD opened at $266.58 on Thursday. The firm has a market capitalization of $18.70 billion, a price-to-earnings ratio of 45.65, a PEG ratio of 4.01 and a beta of 1.22. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The business’s fifty day moving average price is $240.09 and its two-hundred day moving average price is $209.62.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.